OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
779054

Spirit Scientific Co Ltd

Biotechnology & Medical ResearchVerified

Spirit Scientific's capital structure and liquidity position remain opaque due to the absence of balance-sheet inputs and no going-concern language in source documents, preventing a liquidity risk assessment. The company's valuation snapshot is not available, and no liquidity metrics have been computed for further analysis. Profitability and returns data are not available for Spirit Scientific, and no industry-specific metrics have been provided for comparison. Without access to key financial metrics such as ROIC, EBITDA margins, or net profit margins, it is not possible to assess the company's performance relative to industry benchmarks. The company's segments and geographic exposure are not disclosed in the available data. No information is provided on revenue concentration or geographic diversification, making it difficult to evaluate the company's exposure to regional or sector-specific risks. Growth trajectory data is limited, as no outlook figures or revenue history are available. The absence of forward-looking guidance or historical performance metrics prevents an assessment of the company's growth potential or trajectory. Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and the lack of going-concern language in source documents. Dilution risk is currently assessed as low, but no specific dilution sources or adjustments have been identified in the valuation data. Recent events, including filings or transcripts, are not disclosed in the available data. No specific corporate actions or disclosures have been identified that would impact the company's financial position or strategic direction.

30-day price · 7790+7.10 (+13.2%)
Low$44.90High$66.30Close$61.00As of15 May, 00:00 UTC
Profile
CompanySpirit Scientific Co Ltd
Ticker7790.TWO
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. Spirit Scientific Co Ltd is engaged in healthcare diagnostics, providing products and services related to medical testing and analysis.

Classification. Spirit Scientific is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Biotechnology & Medical Research industry, with a confidence level of 0.92.

Spirit Scientific's capital structure and liquidity position remain opaque due to the absence of balance-sheet inputs and no going-concern language in source documents, preventing a liquidity risk assessment. The company's valuation snapshot is not available, and no liquidity metrics have been computed for further analysis. Profitability and returns data are not available for Spirit Scientific, and no industry-specific metrics have been provided for comparison. Without access to key financial metrics such as ROIC, EBITDA margins, or net profit margins, it is not possible to assess the company's performance relative to industry benchmarks. The company's segments and geographic exposure are not disclosed in the available data. No information is provided on revenue concentration or geographic diversification, making it difficult to evaluate the company's exposure to regional or sector-specific risks. Growth trajectory data is limited, as no outlook figures or revenue history are available. The absence of forward-looking guidance or historical performance metrics prevents an assessment of the company's growth potential or trajectory. Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and the lack of going-concern language in source documents. Dilution risk is currently assessed as low, but no specific dilution sources or adjustments have been identified in the valuation data. Recent events, including filings or transcripts, are not disclosed in the available data. No specific corporate actions or disclosures have been identified that would impact the company's financial position or strategic direction.
Key takeaways
  • Spirit Scientific's liquidity and capital structure cannot be assessed due to missing balance-sheet data.
  • No profitability or returns data is available for comparison with industry benchmarks.
  • The company's geographic and segment exposure is not disclosed, limiting risk assessment.
  • Growth trajectory and revenue history are not available, preventing forward-looking analysis.
  • Dilution risk is currently low, but no specific sources or adjustments are identified.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyTWD
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$63.8M-$9.6M-$10.2M-$33.6M
FY-3$123.3M$7.4M$6.0M$7.6M
FY-2$178.9M$8.5M$5.0M$17.1M
FY-1$226.4M$8.3M$5.1M-$42.6M
FY0$273.3M$22.4M$20.1M$43.6M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$175.5M$102.8M$77.2M
FY-3$209.3M$130.5M$98.1M
FY-2$410.2M$314.7M$275.6M
FY-1$450.8M$359.2M$262.3M
FY0$500.5M$388.4M$305.4M
PeriodOCFCapExFCFSBC
FY-4$14.3M-$36.0M-$33.6M
FY-3$27.1M-$14.9M$7.6M
FY-2$19.5M-$7.3M$17.1M
FY-1$22.4M-$65.0M-$42.6M
FY0$47.9M-$4.5M$43.6M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6
FQ-5$55.5M-$367.0k-$498.0k-$38.2M
FQ-4
FQ-3
FQ-2
FQ-1$68.0M$4.6M$4.2M$10.4M
FQ0
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5$397.8M$317.0M$110.1M
FQ-4
FQ-3
FQ-2
FQ-1$499.6M$389.6M$146.1M
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5$3.0M-$47.5M-$38.2M
FQ-4
FQ-3
FQ-2
FQ-1$33.4M-$3.2M$10.4M
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Healthcare Diagnostics · cohort 170 companies
Metric7790Activity
Op margin-227.5% medp25 -1250.6% · p75 -3.5%
Net margin-194.5% medp25 -1233.8% · p75 0.8%
Gross margin53.0% medp25 25.9% · p75 75.7%
CapEx / revenue-8.2% medp25 -35.2% · p75 -2.5%
Debt / equity1.2% medp25 0.0% · p75 17.4%
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-08 08:12 UTC#5041da2c
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 03:19 UTCJob: bc076398